New Treatment of Common Wart
Evaluation Of Intralesional Platelet-Rich Fibrin Versus Intralesional Vitamin D In Treatment Of Common Warts
1 other identifier
interventional
70
1 country
1
Brief Summary
this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts. PRF, as an autologous biological material , may enhance tissue regeneration and immune response.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 1, 2026
CompletedStudy Start
First participant enrolled
April 6, 2026
CompletedFirst Posted
Study publicly available on registry
April 22, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 30, 2026
April 22, 2026
March 1, 2026
8 months
April 1, 2026
April 18, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
treatment of common wart by PRF injection ( Mild response: < 50% reduction in lesion size , Moderate response: ≥ 50% reduction in lesion size , to measure the change in lesion size , is the patient satisfied or not )
treatment of common wart by intralesional injection of PRF
1 session every 2 weeks for 3 months
changes in common warts after treatment by PRF (measuring complete clearance and recurrence of the lesions ,asking about patient satisfaction )
6 months after the last session
Study Arms (2)
group 1 PRF injection
ACTIVE COMPARATORgroup 2 vitamin D injection
ACTIVE COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- \- Age more than or equal to 18 years
- Clinically and dermoscopically confirmed Common warts of both sex
- patient not receiving previous treatment at least one month before recruitment in our study
- Single or multiple lesions suitable for injection.
You may not qualify if:
- Chronic Systemic desise (DM , HTN , Autoimmune , immunosuppressive disorders eg , lupus , renal or hepatic failure ) or Hematologic Conditions (anemia : hemoglobin level below 10 g/dl , thrombocytopenia : platelet count below 150,000 /µL ) Infectious Diseases , Local bacterial or fungal infection at the lesions .
- Pregnancy, Lactation , patients who has hypersensitivity of vitamin D .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Sohag University
Sohag, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dermatology , Venerology and Andrology Resident at Sohag University Hospital
Study Record Dates
First Submitted
April 1, 2026
First Posted
April 22, 2026
Study Start
April 6, 2026
Primary Completion (Estimated)
November 30, 2026
Study Completion (Estimated)
December 30, 2026
Last Updated
April 22, 2026
Record last verified: 2026-03